AstraZeneca, an international biopharmaceutical company, and the National Research Nuclear University MEPhI (Moscow Engineering Physics Institute) have signed a Memorandum of Intent on collaboration in the area of research and education.
The document was signed at 22nd Workshop Conference Project 5 -100, a unique platform for interaction to improve the competitiveness of universities, learn best practices and allow professional community members to share their experience.
The parties want to join their efforts in the comprehensive approach to the development and study of medicinal products and their delivery agents. One of the priority areas for joint collaboration will be the research in the area of translational medicine, personalized medicine, bioinformatics, diagnostic systems and platforms.
Under the agreement, AstraZeneca and MEPhI will also collaborate in educational activities and, in particular, in the area of industrial pharmaceutical science and good practices.
In addition, a great attention will be paid to actively sharing the experience between the divisions of AstraZeneca and MEPhI in the development and study of medicinal products across therapeutic areas that represent a priority for AstraZeneca.